Iovance Biotherapeutics Inc. shares continued a sharp year-to-date rally on Friday, after recently reaching a new 52-week high and gaining more than 250% this year. The stock was down 0.67% at $8.93 in Friday morning trading, according to Benzinga Pro data. With no major company-specific announcement this week, investor interest has been supported by positive interim Phase 3 data from Moderna Inc. and Merck & Co. Inc. showing statistically significant improvements in survival measures for an individualized melanoma treatment. The readout has strengthened sentiment toward advanced melanoma therapies, including Iovance's FDA-approved one-time TIL therapy Amtagvi (lifileucel). Iovance's second-quarter results also exceeded expectations, with sales of $99.313 million, including approximately $91 million in U.S. Amtagvi revenue, and a loss of 11 cents per share versus a 14-cent consensus loss. Management reaffirmed fiscal 2026 sales guidance of $350 million to $370 million, while UBS and Mizuho raised their price targets. Technically, the stock's $9.18 reference price remained well above its 20-day, 50-day, 100-day and 200-day simple moving averages of $5.89, $4.95, $4.33 and $3.60, respectively. An RSI of 83.29 indicated overbought conditions, increasing the risk of consolidation or a sharp pullback. Resistance was identified near $9.36, while $5.89 was the first major trend-support level.